<\/p>\n
Bilkent \u015eehir Hastanesi’nde Ankara \u0130l Sa\u011fl\u0131k M\u00fcd\u00fcr\u00fc Ali Niyazi Kurtcebe, Koordinat\u00f6r Ba\u015fhekim Aziz Ahmet Surel ve uzmanlar\u0131n kat\u0131l\u0131m\u0131yla D\u00fcnya Hepatit G\u00fcn\u00fc fark\u0131ndal\u0131k etkinli\u011fi d\u00fczenlendi.<\/p>\n
Buradaki konu\u015fmas\u0131nda hepatitlerin bula\u015f\u0131c\u0131 hastal\u0131klar\u0131n \u00f6nemli ve b\u00fcy\u00fck bir kolu oldu\u011funa, sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131n\u0131n da s\u0131k s\u0131k hepatit riskiyle kar\u015f\u0131 kar\u015f\u0131ya kald\u0131\u011f\u0131na dikkati \u00e7eken Kurtcebe, “Hepatit A ve Hepatit B a\u015f\u0131lar\u0131 Bakanl\u0131\u011f\u0131m\u0131z\u0131n a\u015f\u0131 takviminde yer al\u0131yor. Bu hastal\u0131\u011fa kar\u015f\u0131 tedbir ve korunman\u0131n yan\u0131nda olmazsa olmaz etken ba\u011f\u0131\u015f\u0131klama yani a\u015f\u0131lanma.” ifadesini kulland\u0131.<\/p>\n
Bilkent \u015eehir Hastanesi Koordinat\u00f6r Ba\u015fhekimi Surel ise hepatit konusunda hem toplumsal hem de sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131 aras\u0131nda fark\u0131ndal\u0131\u011f\u0131n olu\u015fturulmas\u0131n\u0131n b\u00fcy\u00fck \u00f6nem ta\u015f\u0131d\u0131\u011f\u0131n\u0131 ve d\u00fczenlenen etkinlikte de uzmanlar\u0131n bu hastal\u0131\u011fa ili\u015fkin \u00f6nemli bilgileri payla\u015faca\u011f\u0131n\u0131 anlatt\u0131.<\/p>\n
Bilkent \u015eehir Hastanesi Enfeksiyon Hastal\u0131klar\u0131 ve Klinik Mikrobiyoloji Klini\u011fi E\u011fitim ve \u0130dari Sorumlusu Prof. Dr. Rahmet G\u00fcner, etkinlikte hepatitlere ili\u015fkin sunum yapt\u0131.<\/p>\n
Hepatitin sessiz, sinsi ilerleyen bir hastal\u0131k oldu\u011funu, bazen siroz ve kanser a\u015famas\u0131na gelmeden belirti g\u00f6stermedi\u011fini vurgulayan G\u00fcner, “D\u00fcnyada yakla\u015f\u0131k 325 milyon ki\u015finin hepatitten etkilendi\u011fi ve bu ki\u015filerin bir \u00e7o\u011funun tedavi eri\u015fiminin k\u0131s\u0131tl\u0131 oldu\u011fu biliniyor. Ancak bunun yan\u0131 s\u0131ra tedavide \u00e7ok \u00f6nemli mesafeler de kat edildi. A\u015f\u0131lama sayesinde Hepatit A ve Hepatit B’den korunmak m\u00fcmk\u00fcn.” diye konu\u015ftu.<\/p>\n
– “Her 3 yeti\u015fkinden 1’i Hepatit B vir\u00fcs\u00fcyle kar\u015f\u0131la\u015f\u0131yor”<\/p>\n
D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fcn\u00fcn ba\u015flatt\u0131\u011f\u0131 eliminasyon program\u0131 kapsam\u0131nda 2030’a kadar hepatit hastalar\u0131n\u0131n y\u00fczde 90’\u0131n\u0131n tan\u0131 almas\u0131, y\u00fczde 80’inin tedaviye eri\u015fmesi ve hastal\u0131\u011fa ba\u011fl\u0131 \u00f6l\u00fcmlerin de y\u00fczde 65’inin \u00f6nlenmesinin hedeflendi\u011fine dikkati \u00e7eken G\u00fcner, T\u00fcrkiye’de Hepatit B’ye kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k ta\u015f\u0131ma oran\u0131n\u0131n y\u00fczde 4 civar\u0131nda oldu\u011funu dile getirdi.<\/p>\n
Prof. Dr. G\u00fcner, “Buna kar\u015f\u0131n genel olarak elimizdeki g\u00fcncel verilere bakt\u0131\u011f\u0131m\u0131zda, 18 ya\u015f\u0131n \u00fcst\u00fcnde her 3 ki\u015fiden 1’i Hepatit B vir\u00fcs\u00fcyle kar\u015f\u0131la\u015f\u0131yor. B\u00f6lgeler aras\u0131nda da elbette ciddi farkl\u0131l\u0131klar var. Hepatit C a\u00e7\u0131s\u0131ndan da yap\u0131lan \u00e7al\u0131\u015fmalarda farkl\u0131 oranlar bulunsa da pozitiflik oran\u0131n\u0131n 1000’de 5 ile 100’de 1 aras\u0131nda oldu\u011funu s\u00f6yleyebiliriz.” bilgisini payla\u015ft\u0131.<\/p>\n
T\u00fcrkiye’de Hepatit A ve Hepatit B a\u015f\u0131lar\u0131n\u0131n rutin \u00e7ocukluk \u00e7a\u011f\u0131 a\u015f\u0131lamalar\u0131 i\u00e7erisinde yer ald\u0131\u011f\u0131n\u0131, 2018’de Viral Hepatit \u00d6nleme ve Kontrol Program\u0131’n\u0131n yay\u0131mland\u0131\u011f\u0131n\u0131 an\u0131msatan G\u00fcner, “Bu, T\u00fcrkiye’de hepatit konusunda s\u0131k\u0131nt\u0131l\u0131 noktalara nas\u0131l \u00e7\u00f6z\u00fcm bulunaca\u011f\u0131n\u0131 8 ana stratejide derleyen, at\u0131lacak ad\u0131mlar\u0131n net bir \u015fekilde belirlendi\u011fi \u00f6nemli bir program.” dedi.<\/p>\n
Program\u0131n fark\u0131ndal\u0131k \u00e7al\u0131\u015fmalar\u0131, a\u015f\u0131lamaya ve tedaviye eri\u015fim \u00fczerine yo\u011funla\u015ft\u0131\u011f\u0131n\u0131 anlatan G\u00fcner, “Bu program ve \u00f6ncesinde yap\u0131lan \u00e7al\u0131\u015fmalarla, Hepatit A g\u00f6r\u00fclme s\u0131kl\u0131\u011f\u0131nda ve Hepatit B’nin akut formlar\u0131nda belirgin bir azalma sa\u011fland\u0131. \u00dclkemizde y\u00fczde 98’lere varan a\u015f\u0131lama oranlar\u0131 da yeni neslin daha sa\u011fl\u0131kl\u0131 bir \u015fekilde hayata ba\u015flamas\u0131 y\u00f6n\u00fcnde \u00e7ok ciddi bir ad\u0131m.” ifadelerini kulland\u0131.<\/p>\n
Hepatit B’nin anneden bebe\u011fe ge\u00e7i\u015finin \u00f6nlenmesi i\u00e7in anne adaylar\u0131nda, ayr\u0131ca risk grubundaki damar i\u00e7i ila\u00e7 kullan\u0131c\u0131lar\u0131nda hepatit taramalar\u0131n\u0131n zorunlu hale getirildi\u011fini an\u0131msatan G\u00fcner, t\u00fcm bu \u00e7abalara kar\u015f\u0131n Hepatit B ve Hepatit C’nin eri\u015fkin hasta grubunda sinsi bir \u015fekilde devam etti\u011fini, yap\u0131lan bir \u00e7al\u0131\u015fmada hastalar\u0131n fark\u0131ndal\u0131k oran\u0131n\u0131n sadece y\u00fczde 12 olarak g\u00f6sterildi\u011fini kaydetti.<\/p>\n
Prof. Dr. G\u00fcner, DS\u00d6 ve Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 \u00f6nderli\u011finde \u00fclke genelinde hem halka hem de sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131na y\u00f6nelik bilin\u00e7lendirici \u00e7al\u0131\u015fmalar y\u00fcr\u00fct\u00fcld\u00fc\u011f\u00fcn\u00fcn alt\u0131n\u0131 \u00e7izdi.<\/p>\n
Gastroenteroloji Klini\u011fi E\u011fitim G\u00f6revlisi Do\u00e7. Dr. Derya Ar\u0131 da sunumunda hepatit tedavisinde gecikmenin olu\u015fturdu\u011fu ekonomik maliyet ve sa\u011fl\u0131k sistemi \u00fczerindeki y\u00fcke ili\u015fkin bilgileri payla\u015ft\u0131.<\/p>\n